This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
‘The acquisition of BTG and its rapidly growing peripheral interventional portfolio is an exciting extension of our category leadership strategy that will augment our capabilities in important areas of unmet need such as cancer and pulmonary embolism,’ Chairman and CEO of Boston Scientific Mike Mahoney said.
‘We are confident that the addition of these therapies to our portfolio will ultimately advance patient care in ways that could not be realized by either company alone, while also allowing us to realize substantial revenue and cost synergies and provide a strong return for investors,’ he added.
Boston Scientific boosts tech offering
UK-based BTG develops commercial medical tech products that are used in a variety of minimally-invasive surgeries that target cancer and vascular diseases, as well as acute care drugs.
The acquisition by Boston Scientific will see it expand its already large array of medical devices that includes stents, which open damaged blood vessels and reduce the chance of a heart attack or stroke occurring.
‘Boston Scientific shares our commitment to transforming patient care, and has a sustained track record of innovation, clinical expertise and global commercial capabilities,’ CEO of BTG Dame Louise Makin said.
‘The combined organization will be well positioned for success, enabling our valuable products to make a real difference to more people around the world,’ she added.
BTG biggest deal since 2005
BTG shareholders will receive a cash consideration of £8.40 a share, with the deal expected to close in the first half of 2019, subject to regulatory and BTG shareholder approval.
Boston Scientific’s offer represents a 50% premium on BTG’s share price and it the biggest deal the medical device manufacturer has made since it acquired rival Guidant back in 2005 in a deal valued at around $25 billion.
Barclays and Shearman & Sterling are acting as financial and legal advisors on behalf of Boston Scientific.